{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T17:56:50Z","timestamp":1795111010439,"version":"4.10.3"},"reference-count":72,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis pharma","doi-asserted-by":"publisher","award":["SP 006.19"],"award-info":[{"award-number":["SP 006.19"]}],"id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012112","name":"Sobi","doi-asserted-by":"publisher","award":["HCC-4445"],"award-info":[{"award-number":["HCC-4445"]}],"id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Adult-onset Still\u2019s disease (AOSD) is a rare condition characterized by fevers, rash, and arthralgia\/arthritis; most doctors treating AOSD in the Netherlands treat &amp;lt;5 patients per year. Currently, there is no internationally accepted treatment guideline for AOSD. The objectives of this study were to conduct a Delphi panel aimed at reaching consensus about diagnostic and treatment strategies for patients with AOSD and to use the outcomes as a basis for a treatment algorithm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The Delphi panel brought together 18 AOSD experts: rheumatologists, internists and paediatricians. The Delphi process consisted of three rounds. In the first two rounds, online lists of questions and statements were completed. In the third round, final statements were discussed during a virtual meeting and a final vote took place. Consensus threshold was set at 80%. Two targeted literature searches were performed identifying the level of evidence of the consensus-based statements.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Consensus was reached on 29 statements, including statements related to diagnosis and diagnostic tests, definition of response and remission, the therapy, the use of methotrexate and tapering of treatment. The panel consented on reduction of the use of glucocorticoids to avoid side effects, and preferred the use of biologics over conventional treatment. The role of IL-1 and IL-6 blocking agents was considered important in the treatment of AOSD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this Delphi panel, a high level of consensus was achieved on recommendations for diagnosis and therapy of AOSD that can serve as a basis for a treatment guideline.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/kead461","type":"journal-article","created":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T12:20:36Z","timestamp":1693916436000},"page":"1656-1663","source":"Crossref","is-referenced-by-count":49,"title":["Management of adult-onset Still's disease: evidence- and consensus-based recommendations by experts"],"prefix":"10.1093","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8720-3684","authenticated-orcid":false,"given":"Helen L","family":"Leavis","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht , Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L A","family":"van Daele","sequence":"additional","affiliation":[{"name":"Department of Immunology, Erasmus Medical Center , Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8235-2629","authenticated-orcid":false,"given":"Catharina","family":"Mulders-Manders","sequence":"additional","affiliation":[{"name":"Department of Internal medicine, Radboud University Medical Center , Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9e","family":"Michels","sequence":"additional","affiliation":[{"name":"IQVIA , Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Rutgers","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, University Medical Center Groningen , Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Legger","sequence":"additional","affiliation":[{"name":"Department of Pediatric Rheumatology, University Medical Center Groningen , Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Bijl","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Martini Hospital , Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth A","family":"Hak","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center , Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai-Kwan","family":"Lam-Tse","sequence":"additional","affiliation":[{"name":"Department Rheumatology, Franciscus Hospital , Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke","family":"Bonte-Mineur","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Maasstad Hospital , Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Fretter","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Treant Hospitals , Emmen\/Hoogeveen\/Stadskanaal, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Simon","sequence":"additional","affiliation":[{"name":"Department of Internal medicine, Radboud University Medical Center , Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"van Paassen","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Clinical Immunology, Maastricht University Medical Center , Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies C","family":"van der Goes","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Meander Medical Center , Amersfoort, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Flendrie","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Maartenskliniek , Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ward","family":"Vercoutere","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Reumazorg Zuid-West Nederland , Goes-Terneuzen-Oostburg, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine W T","family":"van Lieshout","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Jeroen Bosch Ziekenhuis , \u2019s-Hertogenbosch, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjen","family":"Leek","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University Medical Center Utrecht , Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiaan J","family":"Vastert","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University Medical Center Utrecht , Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander W","family":"Tas","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center , Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,5]]},"reference":[{"key":"2024060322013752600_kead461-B1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jaut.2018.07.018","article-title":"A comprehensive review on adult onset Still's disease","volume":"93","author":"Giacomelli","year":"2018","journal-title":"J Autoimmun"},{"key":"2024060322013752600_kead461-B2","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1080\/1744666X.2017.1332994","article-title":"Treatment of adult-onset still's disease: up to date","volume":"13","author":"Yoo","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"2024060322013752600_kead461-B3","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s13075-019-2021-9","article-title":"Management of adult-onset Still's disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts","volume":"21","author":"Colafrancesco","year":"2019","journal-title":"Arthritis research & therapy"},{"key":"2024060322013752600_kead461-B4","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1046\/j.1365-2648.2000.t01-1-01567.x","article-title":"Research guidelines for the Delphi survey technique","volume":"32","author":"Hasson","year":"2000","journal-title":"J Adv Nurs"},{"key":"2024060322013752600_kead461-B5","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1097\/ACM.0000000000001812","article-title":"The use of the Delphi and other consensus group methods in medical education research: a review","volume":"92","author":"Humphrey-Murto","year":"2017","journal-title":"Acad Med"},{"key":"2024060322013752600_kead461-B6","article-title":"The SHARE recommendations on diagnosis and treatment of systemic JIA (abstract)","author":"Leek","year":"2020"},{"key":"2024060322013752600_kead461-B7","doi-asserted-by":"crossref","first-page":"vi9","DOI":"10.1093\/rheumatology\/kez350","article-title":"Anakinra in children and adults with Still's disease","volume":"58","author":"Vastert","year":"2019","journal-title":"Rheumatology"},{"key":"2024060322013752600_kead461-B8","author":"NVK Richtlijn","year":"2018"},{"key":"2024060322013752600_kead461-B9","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"2024060322013752600_kead461-B10","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","article-title":"Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies","volume":"67","author":"Diamond","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"2024060322013752600_kead461-B11","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.0736-8046.2004.21513.x","article-title":"A pruritic linear urticarial rash, fever, and systemic inflammatory disease in five adolescents: adult-onset still disease or systemic juvenile idiopathic arthritis sine arthritis?","volume":"21","author":"Prendiville","year":"2004","journal-title":"Pediatr Dermatol"},{"key":"2024060322013752600_kead461-B12","doi-asserted-by":"crossref","first-page":"e15123","DOI":"10.1097\/MD.0000000000015123","article-title":"Managing Adult-onset Still's disease: the effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study","volume":"98","author":"Ruscitti","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"2024060322013752600_kead461-B13","doi-asserted-by":"crossref","first-page":"831","DOI":"10.2165\/00003495-199958050-00006","article-title":"Medical management of children with juvenile rheumatoid arthritis","volume":"58","author":"Cassidy","year":"1999","journal-title":"Drugs"},{"key":"2024060322013752600_kead461-B14","first-page":"33","article-title":"Treatment of adult-onset Still's disease: a review","volume":"11","author":"Jamilloux","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"2024060322013752600_kead461-B15","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/art.38296","article-title":"Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study","volume":"66","author":"Vastert","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2024060322013752600_kead461-B16","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/art.40865","article-title":"Treatment to target using recombinant interleukin-1 receptor antagonist as first-line monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five-year follow-up study","volume":"71","author":"Ter Haar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2024060322013752600_kead461-B17","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.semarthrit.2017.06.006","article-title":"Adult onset Still's disease-The evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review)","volume":"47","author":"Junge","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2024060322013752600_kead461-B18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ard.2008.088179","article-title":"Tocilizumab for multirefractory adult-onset Still's disease","volume":"68","author":"De Bandt","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2024060322013752600_kead461-B19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13075-019-1838-6","article-title":"Adult-onset Still's disease biological treatment strategy may depend on the phenotypic dichotomy","volume":"21","author":"Vercruysse","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2024060322013752600_kead461-B20","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1136\/annrheumdis-2018-213920","article-title":"Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial","volume":"77","author":"Kaneko","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2024060322013752600_kead461-B21","doi-asserted-by":"crossref","first-page":"13477","DOI":"10.1038\/s41598-017-13639-y","article-title":"A pilot study on tocilizumab for treating refractory adult-onset Still's disease","volume":"7","author":"Li","year":"2017","journal-title":"Sci Rep"},{"key":"2024060322013752600_kead461-B22","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1080\/14397595.2017.1416924","article-title":"Efficacy and safety of tocilizumab with inhibition of interleukin-6 in adult-onset Still's disease: a meta-analysis","volume":"28","author":"Ma","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2024060322013752600_kead461-B23","first-page":"S64","article-title":"Efficacy of tocilizumab therapy in Korean patients with adult-onset Still's disease: a multicentre retrospective study of 22 cases","volume":"34","author":"Song","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2024060322013752600_kead461-B24","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3109\/14397595.2014.899178","article-title":"Successful tocilizumab therapy in seven patients with refractory adult-onset Still's disease","volume":"26","author":"Bannai","year":"2016","journal-title":"Mod Rheumatol"},{"key":"2024060322013752600_kead461-B25","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/art.38398","article-title":"Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: multicenter retrospective open-label study of thirty-four patients","volume":"66","author":"Ortiz-Sanjuan","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2024060322013752600_kead461-B26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10067-013-2381-5","article-title":"Tocilizumab for the treatment of adult-onset Still's disease: results from a case series","volume":"33","author":"Cipriani","year":"2014","journal-title":"Clin Rheumatol"},{"key":"2024060322013752600_kead461-B27","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3109\/s10165-011-0569-6","article-title":"Therapeutic response of patients with adult Still's disease to biologic agents: multicenter results in Japan","volume":"22","author":"Suematsu","year":"2012","journal-title":"Mod Rheumatol"},{"key":"2024060322013752600_kead461-B28","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/acr.20319","article-title":"Tocilizumab in refractory adult Still's disease","volume":"63","author":"Puechal","year":"2011","journal-title":"Arthritis Care Res"},{"key":"2024060322013752600_kead461-B29","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3899\/jrheum.130881","article-title":"Tocilizumab in adult-onset Still's disease: the Israeli experience","volume":"41","author":"Elkayam","year":"2014","journal-title":"J Rheumatol"},{"key":"2024060322013752600_kead461-B30","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3109\/14397595.2014.973659","article-title":"The effect of tocilizumab on preventing relapses in adult-onset Still's disease: a retrospective, single-center study","volume":"25","author":"Nishina","year":"2015","journal-title":"Mod Rheumatol"},{"key":"2024060322013752600_kead461-B31","doi-asserted-by":"crossref","first-page":"iii55","DOI":"10.1136\/ard.60.90003.iii55","article-title":"Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences","volume":"60(Suppl 3)","author":"Kraetsch","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"2024060322013752600_kead461-B32","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/ard.2004.024026","article-title":"Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases","volume":"64","author":"Fautrel","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2024060322013752600_kead461-B33","first-page":"121","article-title":"Prolonged efficacy of infliximab for refractory adult-onset Still's disease","volume":"23","author":"Dilhuydy","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2024060322013752600_kead461-B34","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2147\/TCRM.S155488","article-title":"Biological therapy of traditional therapy-resistant adult-onset Still's disease: an evidence-based review","volume":"14","author":"Zhou","year":"2018","journal-title":"Ther Clin Risk Manag"},{"key":"2024060322013752600_kead461-B35","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10067-009-1331-8","article-title":"Successful treatment of refractory adult Still's disease and membranous glomerulonephritis with infliximab","volume":"29","author":"Babacan","year":"2010","journal-title":"Clin Rheumatol"},{"key":"2024060322013752600_kead461-B36","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/ard.2010.129403","article-title":"Successful treatment of adult-onset Still's disease refractory to TNF and IL-1 blockade by IL-6 receptor blockade","volume":"70","author":"Rech","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2024060322013752600_kead461-B37","first-page":"373","article-title":"Corticosteroid sparing effect of low dose methotrexate treatment in adult Still's disease","volume":"26","author":"Fautrel","year":"1999","journal-title":"J Rheumatol"},{"key":"2024060322013752600_kead461-B38","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaut.2016.02.010","article-title":"Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still's disease: data from a large multicenter cohort","volume":"69","author":"Kalyoncu","year":"2016","journal-title":"J Autoimmun"},{"key":"2024060322013752600_kead461-B39","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s10067-005-0138-5","article-title":"A multicenter study of patients with adult-onset Still's disease compared with systemic juvenile idiopathic arthritis","volume":"25","author":"Pay","year":"2006","journal-title":"Clin Rheumatol"},{"key":"2024060322013752600_kead461-B40","first-page":"47","article-title":"Adult-onset Still's disease: clinical, serological and therapeutic considerations","volume":"31","author":"Iliou","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2024060322013752600_kead461-B41","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1002\/art.27532","article-title":"Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still's disease","volume":"62","author":"Franchini","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2024060322013752600_kead461-B42","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1136\/ard.56.2.144","article-title":"Methotrexate treatment in patients with adult onset Still's disease\u2013retrospective study of 13 Japanese cases","volume":"56","author":"Fujii","year":"1997","journal-title":"Ann Rheum Dis"},{"key":"2024060322013752600_kead461-B43","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10067-007-0648-4","article-title":"Adult onset Still's disease: a study of 14 cases","volume":"27","author":"Singh","year":"2008","journal-title":"Clin Rheumatol"},{"key":"2024060322013752600_kead461-B44","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.3899\/jrheum.111549","article-title":"Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study","volume":"39","author":"Nordstrom","year":"2012","journal-title":"J Rheumatol"},{"key":"2024060322013752600_kead461-B45","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1002\/1529-0131(200008)43:8<1849::AID-ANR22>3.0.CO;2-F","article-title":"Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis","volume":"43","author":"Woo","year":"2000","journal-title":"Arthritis Rheum"},{"key":"2024060322013752600_kead461-B46","first-page":"431","article-title":"Low dose methotrexate treatment in adult Still's disease","volume":"19","author":"Aydintug","year":"1992","journal-title":"J Rheumatol"},{"key":"2024060322013752600_kead461-B47","first-page":"S168","article-title":"Use of methotrexate in adult-onset Still's disease","volume":"28","author":"Manger","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"2024060322013752600_kead461-B48","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.berh.2008.08.006","article-title":"Adult-onset Still disease","volume":"22","author":"Fautrel","year":"2008","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2024060322013752600_kead461-B49","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2165\/00003495-200868030-00005","article-title":"Adult-onset Still's disease: pathogenesis, clinical manifestations and therapeutic advances","volume":"68","author":"Kontzias","year":"2008","journal-title":"Drugs"},{"key":"2024060322013752600_kead461-B50","first-page":"424","article-title":"Preliminary criteria for classification of adult Still's disease","volume":"19","author":"Yamaguchi","year":"1992","journal-title":"J Rheumatol"},{"key":"2024060322013752600_kead461-B51","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.semarthrit.2021.06.004","article-title":"Adult-onset Still's disease in focus: clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies","volume":"51","author":"Efthimiou","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2024060322013752600_kead461-B52","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41584-018-0081-x","article-title":"Mechanisms, biomarkers and targets for adult-onset Still's disease","volume":"14","author":"Feist","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2024060322013752600_kead461-B53","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/art.30128","article-title":"Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series","volume":"63","author":"Nigrovic","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2024060322013752600_kead461-B54","doi-asserted-by":"crossref","first-page":"e16682","DOI":"10.1097\/MD.0000000000016682","article-title":"Refractory adult-onset Still disease treated by tocilizumab combined with methotrexate: a STROBE-compliant article","volume":"98","author":"Wang","year":"2019","journal-title":"Medicine"},{"key":"2024060322013752600_kead461-B55","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3109\/s10165-011-0477-9","article-title":"Adult-onset Still's disease with macrophage activation syndrome successfully treated with a combination of methotrexate and etanercept","volume":"22","author":"Maeshima","year":"2012","journal-title":"Mod Rheumatol"},{"key":"2024060322013752600_kead461-B56","first-page":"923497","article-title":"Successful use of higher-dose etanercept for multirefractory systemic flare of adult-onset Still's disease with liver failure with no response to tocilizumab therapy","volume":"2013","author":"Naniwa","year":"2013","journal-title":"Case Rep Rheumatol"},{"key":"2024060322013752600_kead461-B57","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.amjmed.2012.08.003","article-title":"Reversal of severe hepatitis with infliximab in adult-onset Still's disease","volume":"126","author":"Singh","year":"2013","journal-title":"Am J Med"},{"key":"2024060322013752600_kead461-B58","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2024060322013752600_kead461-B59","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/CCM.0000000000001402","article-title":"Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial","volume":"44","author":"Shakoory","year":"2016","journal-title":"Crit Care Med"},{"key":"2024060322013752600_kead461-B60","doi-asserted-by":"crossref","first-page":"e690","DOI":"10.1016\/S2665-9913(21)00216-2","article-title":"Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis","volume":"3","author":"Kyriazopoulou","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2024060322013752600_kead461-B61","first-page":"163952","article-title":"Successful treatment with intravenous cyclophosphamide for refractory adult-onset Still's disease","volume":"2015","author":"Tsuji","year":"2015","journal-title":"Case Rep Rheumatol"},{"key":"2024060322013752600_kead461-B62","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1590\/S1516-31802003000300006","article-title":"Treatment of refractory juvenile idiopathic arthritis via pulse therapy using methylprednisolone and cyclophosphamide","volume":"121","author":"de Castro","year":"2003","journal-title":"Sao Paulo Med J"},{"key":"2024060322013752600_kead461-B63","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/BF02242954","article-title":"Polyserositis in adult Still's disease with onset during pregnancy [corrected]","volume":"13","author":"Falkenbach","year":"1994","journal-title":"Clin Rheumatol"},{"key":"2024060322013752600_kead461-B64","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3904\/kjim.2014.292","article-title":"Cyclophosphamide therapy for secondary amyloidosis in a patient with juvenile idiopathic arthritis unresponsive to tumor necrosis factor alpha inhibitor therapy","volume":"31","author":"Han","year":"2016","journal-title":"Korean J Intern Med"},{"key":"2024060322013752600_kead461-B65","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1038\/sj.bmt.1702435","article-title":"Prolonged remission state of refractory adult onset Still's disease following CD34-selected autologous peripheral blood stem cell transplantation","volume":"25","author":"Lanza","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"2024060322013752600_kead461-B66","first-page":"295","article-title":"Intravenous immunoglobulin in adult Still's disease refractory to non-steroidal anti-inflammatory drugs","volume":"16","author":"Vignes","year":"1998","journal-title":"Clin Exp Rheumatol"},{"key":"2024060322013752600_kead461-B67","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1007\/s10067-022-06184-1","article-title":"Short-term, low-dose etoposide in refractory adult-onset Still's disease-associated macrophage activation syndrome","volume":"41","author":"Wang","year":"2022","journal-title":"Clin Rheumatol"},{"key":"2024060322013752600_kead461-B68","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1002\/art.38802","article-title":"Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients","volume":"66","author":"Minoia","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2024060322013752600_kead461-B69","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1136\/ard-2022-223739","article-title":"Efficacy and safety of emapalumab in macrophage activation syndrome","volume":"82","author":"De Benedetti","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2024060322013752600_kead461-B70","first-page":"840","article-title":"Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease","volume":"77","author":"Gabay","year":"2018","journal-title":"Annals of the rheumatic diseases"},{"key":"2024060322013752600_kead461-B71","author":"PNDS"},{"key":"2024060322013752600_kead461-B72","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1080\/14397595.2018.1465633","article-title":"Evidence-based clinical practice guideline for adult Still's disease","volume":"28","author":"Mimura","year":"2018","journal-title":"Mod Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/kead461\/51718232\/kead461.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/6\/1656\/58064747\/kead461.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/6\/1656\/58064747\/kead461.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,27]],"date-time":"2024-10-27T07:30:14Z","timestamp":1730014214000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/63\/6\/1656\/7260500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,5]]},"references-count":72,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,9,5]]},"published-print":{"date-parts":[[2024,5,3]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/kead461","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6,1]]},"published":{"date-parts":[[2023,9,5]]}}}